Cheelcare Inc (CHER) Q2 2026 earnings summary

Executive summary

• Completed transition to a new 16,000 sq. ft. manufacturing facility, enabling operational scale-up and pilot production of the Curio robotic wheelchair.

• Expanded global dealer network to over 500 locations, including more than 20 U.S. Veterans Affairs Medical Centers.

• Launched an updated Companion product with enhanced features and usability.

Financial highlights

• Gross revenue was $459,158, down from $510,673 in Q2 2024; net revenue was $391,939, down from $431,277 year-over-year.

• Gross profit reached $228,141 with a gross margin of approximately 58%.

• Net loss and comprehensive loss widened to $(547,451), or $(0.03) per share, compared to $(34,060), or $(0.00) per share in Q2 2024.

• Adjusted EBITDA loss was $(481,857) for the quarter.

• Cash and cash equivalents stood at $848,605, with working capital of $1,027,139 as of October 31, 2025.

Outlook and guidance

• Early commercialization of Curio is underway, with expectations to convert regulatory milestones into revenue growth.